SRR1437538
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.475
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.334
- KRAS_SIGNALING_DN+0.332
- SPERMATOGENESIS+0.252
- PANCREAS_BETA_CELLS+0.241
- UV_RESPONSE_UP+0.165
- MYOGENESIS+0.159
- FATTY_ACID_METABOLISM+0.143
- MYC_TARGETS_V2+0.115
- XENOBIOTIC_METABOLISM+0.091
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.548
- INTERFERON_GAMMA_RESPONSE-0.463
- NOTCH_SIGNALING-0.457
- IL6_JAK_STAT3_SIGNALING-0.442
- G2M_CHECKPOINT-0.409
- TGF_BETA_SIGNALING-0.397
- E2F_TARGETS-0.373
- INFLAMMATORY_RESPONSE-0.363
- ALLOGRAFT_REJECTION-0.348
- WNT_BETA_CATENIN_SIGNALING-0.339
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1416477 | GTEX | — | 0.928 |
| 2 | SRR810877 | GTEX | — | 0.924 |
| 3 | SRR1468381 | GTEX | — | 0.923 |
| 4 | SRR1435775 | GTEX | — | 0.922 |
| 5 | SRR1435020 | GTEX | — | 0.920 |
| 6 | SRR1474777 | GTEX | — | 0.919 |
| 7 | SRR1085825 | GTEX | — | 0.917 |
| 8 | SRR1355040 | GTEX | — | 0.917 |
| 9 | SRR1468955 | GTEX | — | 0.917 |
| 10 | SRR1387199 | GTEX | — | 0.909 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.475 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.334 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.332 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.252 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.241 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.165 | Idelalisib | — uncovered |
| MYOGENESIS | 0.159 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.143 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.115 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.091 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.077 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.076 | Inavolisib | — uncovered |
| COAGULATION | 0.061 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.045 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.039 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |